The efficacy and long-term impact of different doses of statins in patients with acute coronary syndrome.

IF 2 4区 医学 Q3 PHYSIOLOGY
Journal of Physiology and Pharmacology Pub Date : 2024-12-01 Epub Date: 2025-02-03 DOI:10.26402/jpp.2024.6.02
H Chen, Y M Hao
{"title":"The efficacy and long-term impact of different doses of statins in patients with acute coronary syndrome.","authors":"H Chen, Y M Hao","doi":"10.26402/jpp.2024.6.02","DOIUrl":null,"url":null,"abstract":"<p><p>We aimed to evaluate the clinical efficacy of different doses of atorvastatin in patients with acute coronary syndrome (ACS) following percutaneous coronary intervention (PCI). In this prospective, randomized controlled study, we enrolled 147 patients with ACS who underwent PCI at our hospital between April 2020 and June 2021. Participants were randomly assigned to three groups based on their post-PCI atorvastatin dose: low-dose (20 mg/day, n=49), medium-dose (40 mg/day, n=49), and high-dose (80 mg/day, n=49). We assessed clinical parameters including blood lipid profiles, inflammatory marker levels, creatine kinase (CK) levels and liver and kidney function before and after atorvastatin treatment. Adverse reactions were monitored to evaluate the safety and efficacy of the different atorvastatin doses. The mean follow-up duration was 13.76±1.27 months (range 12-15 months). No significant differences in baseline blood lipid levels, CK levels and inflammatory markers were observed among the groups (all P>0.05). Post-treatment, the high-dose atorvastatin group showed a more pronounced reduction in blood lipid levels and higher CK levels compared to the medium-dose and low-dose groups. Similarly, the medium-dose group had better outcomes than the low-dose group, with these differences being statistically significant (P<0.05). The high-dose group also exhibited significantly lower levels of inflammatory markers than both the medium-dose and low-dose groups after treatment (P<0.05). Adverse reactions were relatively infrequent across all groups: 4.08% in the low-dose group (1 case of nausea, 1 case of insomnia), 8.16% in the medium-dose group (1 case of insomnia, 1 case of dyspnea, 1 case of nausea, and 1 case of muscular soreness ), and 16.33% in the high-dose group (2 cases of nausea, 1 case of dyspnea, 2 cases of insomnia, and 3 cases of muscular soreness). There was no statistically significant difference in the incidence of adverse reactions among the groups (χ<sup>2</sup>=4.421, P=0.110). To sum up the results, high-dose atorvastatin significantly improved blood lipid profiles and reduced inflammatory markers in ACS patients following PCI, without adversely affecting liver or kidney function. Furthermore, the high-dose regimen demonstrated a favorable safety profile, suggesting its potential benefit in managing these patients population.</p>","PeriodicalId":50089,"journal":{"name":"Journal of Physiology and Pharmacology","volume":"75 6","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Physiology and Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26402/jpp.2024.6.02","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHYSIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

We aimed to evaluate the clinical efficacy of different doses of atorvastatin in patients with acute coronary syndrome (ACS) following percutaneous coronary intervention (PCI). In this prospective, randomized controlled study, we enrolled 147 patients with ACS who underwent PCI at our hospital between April 2020 and June 2021. Participants were randomly assigned to three groups based on their post-PCI atorvastatin dose: low-dose (20 mg/day, n=49), medium-dose (40 mg/day, n=49), and high-dose (80 mg/day, n=49). We assessed clinical parameters including blood lipid profiles, inflammatory marker levels, creatine kinase (CK) levels and liver and kidney function before and after atorvastatin treatment. Adverse reactions were monitored to evaluate the safety and efficacy of the different atorvastatin doses. The mean follow-up duration was 13.76±1.27 months (range 12-15 months). No significant differences in baseline blood lipid levels, CK levels and inflammatory markers were observed among the groups (all P>0.05). Post-treatment, the high-dose atorvastatin group showed a more pronounced reduction in blood lipid levels and higher CK levels compared to the medium-dose and low-dose groups. Similarly, the medium-dose group had better outcomes than the low-dose group, with these differences being statistically significant (P<0.05). The high-dose group also exhibited significantly lower levels of inflammatory markers than both the medium-dose and low-dose groups after treatment (P<0.05). Adverse reactions were relatively infrequent across all groups: 4.08% in the low-dose group (1 case of nausea, 1 case of insomnia), 8.16% in the medium-dose group (1 case of insomnia, 1 case of dyspnea, 1 case of nausea, and 1 case of muscular soreness ), and 16.33% in the high-dose group (2 cases of nausea, 1 case of dyspnea, 2 cases of insomnia, and 3 cases of muscular soreness). There was no statistically significant difference in the incidence of adverse reactions among the groups (χ2=4.421, P=0.110). To sum up the results, high-dose atorvastatin significantly improved blood lipid profiles and reduced inflammatory markers in ACS patients following PCI, without adversely affecting liver or kidney function. Furthermore, the high-dose regimen demonstrated a favorable safety profile, suggesting its potential benefit in managing these patients population.

不同剂量他汀类药物对急性冠脉综合征患者的疗效及远期影响。
本研究旨在评价不同剂量阿托伐他汀在急性冠脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)后的临床疗效。在这项前瞻性、随机对照研究中,我们招募了147名ACS患者,这些患者于2020年4月至2021年6月在我院接受了PCI治疗。参与者根据pci术后阿托伐他汀剂量随机分为三组:低剂量(20mg /天,n=49)、中剂量(40mg /天,n=49)和高剂量(80mg /天,n=49)。我们评估了阿托伐他汀治疗前后的临床参数,包括血脂、炎症标志物水平、肌酸激酶(CK)水平和肝肾功能。监测不良反应,评价不同剂量阿托伐他汀的安全性和有效性。平均随访时间13.76±1.27个月(12 ~ 15个月)。各组基线血脂水平、CK水平及炎症指标差异均无统计学意义(P < 0.05)。治疗后,与中剂量和低剂量组相比,高剂量阿托伐他汀组的血脂水平下降更明显,CK水平更高。同样,中剂量组疗效优于低剂量组,差异有统计学意义(P2=4.421, P=0.110)。综上所述,大剂量阿托伐他汀可显著改善ACS患者PCI术后血脂谱,降低炎症标志物,且未对肝肾功能产生不良影响。此外,高剂量方案显示出良好的安全性,表明其在管理这些患者群体中的潜在益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.00
自引率
22.70%
发文量
0
审稿时长
6-12 weeks
期刊介绍: Journal of Physiology and Pharmacology publishes papers which fall within the range of basic and applied physiology, pathophysiology and pharmacology. The papers should illustrate new physiological or pharmacological mechanisms at the level of the cell membrane, single cells, tissues or organs. Clinical studies, that are of fundamental importance and have a direct bearing on the pathophysiology will also be considered. Letters related to articles published in The Journal with topics of general professional interest are welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信